Clin2
NCT06894784Possibly a fitRecruiting

Combining two diabetes drugs with an automated insulin pump

Diabetes Type 1

Part of Hormones & metabolism, Immune system & allergy clinical trials.

This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
36 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have had type 1 diabetes for at least one year.
  • You have been using an automated insulin delivery (AID) system for at least three months.
  • Your body mass index (BMI) is 23 or higher.
  • You have not used a GLP-1 receptor agonist (like Ozempic) in the last month or an SGLT2 inhibitor (like Jardiance) in the last two weeks.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06387199Recruiting· Phase 2/Phase 3
Weekly semaglutide with closed-loop system for type 1 diabetes

This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.

Montreal, Quebec
NCT06021145Recruiting· Phase 4
Adding empagliflozin to insulin pumps for type 1 diabetes

This study tests whether adding the diabetes pill empagliflozin (Jardiance) to your current automated insulin pump can help improve blood sugar control for adults with type 1 diabetes who are not reaching their glucose goals.

Montreal, Quebec
NCT06762314Recruiting· Phase 2
Empagliflozin or semaglutide for overweight people with type 1 diabetes

This study tests two different medicines (empagliflozin or semaglutide) added to your usual insulin to see if they help with blood sugar control and weight loss in people with type 1 diabetes who are overweight or have obesity. It may be a good fit if your diabetes is not well controlled with insulin injections alone.

Tanta
NCT06613854Recruiting· Phase 4
Early combination therapy for type 2 diabetes

This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.

Ljubljana
NCT05819138Recruiting· Phase 3
Semaglutide for heart outcomes in adults with type 1 diabetes

This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.

Aurora, Colorado
NCT06909006Not yet recruiting· Phase 3
Semaglutide for type 1 diabetes with higher body weight

This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.

Hillerød, Denmark

Hear when a new Diabetes Type 1 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.